Article Per Year (5 Year)
p-Index From 2020 - 2025
0.751
P-Index
This Author published in this journals
All Journal IJRETINA - International Journal of Retina Ophthalmologica Indonesiana
Ardhia, Seruni Hanna
Unknown Affiliation
Health Professions Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Simple Encircling Scleral Band for Uncomplicated Retinal Detachment Djatikusumo, Ari; Sjahreza, Emil Fahrinandi; Triwijayanti, Triwijayanti; Taim, Abisyifa Rahma; Ardhia, Seruni Hanna
International Journal of Retina Vol 7 No 1 (2024): International Journal of Retina (IJRetina) - INAVRS
Publisher : Indonesian Vitreoretinal Society

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35479/ijretina.2024.vol007.iss001.258

Abstract

Introduction: Report the surgical and visual outcome of using a narrow band in encircling scleral buckling for selected rhegmatogenous retinal detachment (RRD). Methods: A retrospective case series review of 16 patients with primary RRD treated with encircling scleral buckling using a narrow band 240 (2.5 mm) in KMN Eye Care from June 2018 to June 2020. Results: A total of 16 eyes in 16 patients with RRD underwent encircling scleral buckling with a narrow silicone band 240 (2.5 mm) without any additional tire or sponge. All patients have myopic eyes, with the mean pre-operative best-corrected visual acuity (BCVA) is less than 0.50. The primary success rate of retinal reattachment was 81.25%. Three patients had retinal re-detachment within one month post-surgery, and 2 patients had persistent sub-macular fluid, despite retinal reattachment. In patients with retinal reattachment, the BCVA showed improvement better than 0.5 at 1-month follow-up (9 patients, 69.2%). Spherical equivalent changes before and after scleral buckling were -1.90 D. Conclusion: Narrow encircling scleral buckle surgery can be considered an effective and safe technique in selected RRDs, including anteriorly located, multiple, or invisible retinal breaks. A further, large-size randomized controlled study is needed to confirm its efficacy.
Reducing Treatment Burden for Age-Related Macular Degeneration Patients: A Systematic Review of Ranibizumab Port Delivery System: Oral Presentation - Observational Study - General practitioner Paramitha, Dewa Ayu Anggi; Putri, Ajeng Kartika Ayu; Ardhia, Seruni Hanna; Jutamulia, Jovita
Majalah Oftalmologi Indonesia Vol 49 No S2 (2023): Supplement Edition
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/v8vmp587

Abstract

Introduction & ObjectivesRanibizumab port delivery system (PDS) is a newly developed method that provides a continuous,long-term supply of ranibizumab into the vitreous, reducing the burden of monthly intravitrealinjection visits for neovascular age-related macular degeneration (nAMD) patients. This review aimsto evaluate the efficacy and safety of ranibizumab PDS in nAMD. MethodsAn extensive literature search was performed on 4 online databases: PubMed, Cochrane, ProQuest,and ScienceDirect. The inclusion criteria are human studies comparing ranibizumab port deliverysystem and intravitreal ranibizumab, English language, with full-text journal available. The mainoutcome measurements are best-corrected visual acuity (BCVA) in Early Treatment DiabeticRetinopathy Study (ETDRS) letters, central foveal thickness (CFT), and adverse events. ResultsTwo randomized controlled trials (RCTs) with a total of 638 adults were evaluated. At week 96,ranibizumab PDS reported observed mean BCVA changes from baseline (-1.0; +4.2; ETDRS letters)compared to monthly intravitreal ranibizumab (-1.1; +6.1; ETDRS letters). However, there was anincrease in mean CFT changes from baseline (+9.9; +22.3 vs ?1.3; ?35.8, ?m) and severe adverseevents frequency (22; 4 vs 4; 0) with ranibizumab PDS versus monthly intravitreal ranibizumab,respectively. ConclusionRanibizumab PDS showed comparable visual outcomes to intravitreal ranibizumab whiledemonstrating inferior anatomical outcomes and higher incidence of severe adverse effects. Despitethis, with fewer treatment visits required for up to 24 weeks, ranibizumab PDS can potentiallyreduce the treatment burden in nAMD patients with poor compliance. Further studies are needed toprovide better patient eligibility guidelines and recommendations for adverse event management ofranibizumab PDS.
Reducing Treatment Burden for Age-Related Macular Degeneration Patients: A Systematic Review of Ranibizumab Port Delivery System Paramitha, Dewa Ayu Anggi; Putri, Ajeng Kartika Ayu; Ardhia, Seruni Hanna; Jutamulia, Jovita
Majalah Oftalmologi Indonesia Vol 49 No S2 (2023): Supplement Edition
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/zh73sh38

Abstract

Introduction & ObjectivesRanibizumab port delivery system (PDS) is a newly developed method that provides a continuous,long-term supply of ranibizumab into the vitreous, reducing the burden of monthly intravitrealinjection visits for neovascular age-related macular degeneration (nAMD) patients. This review aimsto evaluate the efficacy and safety of ranibizumab PDS in nAMD. MethodsAn extensive literature search was performed on 4 online databases: PubMed, Cochrane, ProQuest,and ScienceDirect. The inclusion criteria are human studies comparing ranibizumab port deliverysystem and intravitreal ranibizumab, English language, with full-text journal available. The mainoutcome measurements are best-corrected visual acuity (BCVA) in Early Treatment DiabeticRetinopathy Study (ETDRS) letters, central foveal thickness (CFT), and adverse events. ResultsTwo randomized controlled trials (RCTs) with a total of 638 adults were evaluated. At week 96,ranibizumab PDS reported observed mean BCVA changes from baseline (-1.0; +4.2; ETDRS letters)compared to monthly intravitreal ranibizumab (-1.1; +6.1; ETDRS letters). However, there was anincrease in mean CFT changes from baseline (+9.9; +22.3 vs ?1.3; ?35.8, ?m) and severe adverseevents frequency (22; 4 vs 4; 0) with ranibizumab PDS versus monthly intravitreal ranibizumab,respectively. ConclusionRanibizumab PDS showed comparable visual outcomes to intravitreal ranibizumab whiledemonstrating inferior anatomical outcomes and higher incidence of severe adverse effects. Despitethis, with fewer treatment visits required for up to 24 weeks, ranibizumab PDS can potentiallyreduce the treatment burden in nAMD patients with poor compliance. Further studies are needed toprovide better patient eligibility guidelines and recommendations for adverse event management ofranibizumab PDS.
Co-Authors Djatikusumo, Ari Jutamulia, Jovita Paramitha, Dewa Ayu Anggi Putri, Ajeng Kartika Ayu Sjahreza, Emil Fahrinandi Taim, Abisyifa Rahma Triwijayanti, Triwijayanti